MedDataX Logo

The Interval Between the Time of Second PEG Dose and the Start of the Colonoscopy

NCT ID: NCT01286961

Last Updated: 2011-10-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

360 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

As the duration of the interval between the time of last preparation-agent dose and the start of the colonoscopy is increasing, the quality of bowel preparation will be worse.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the present studies is to determine how the duration of the interval of the time of last preparation dose and the start of colonoscopy affects the quality of the bowel preparation and when the proper timing of the colonoscopy is after completion of last preparation regimen

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

The Timing of Bowel Preparation in Outpatient Colonoscopy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

outpatient colonoscopy, bowel preparation, split dose PEG

adult outpatients who undergo colonoscopy

bowel preparation using split dose of polyethylene glycol

Intervention Type DRUG

polyethylene glycol, split dose(2L/2L), each dose for 1-2hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bowel preparation using split dose of polyethylene glycol

polyethylene glycol, split dose(2L/2L), each dose for 1-2hours

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Colyte

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult outpatients(18-85 years of age) who undergo colonoscopy for screening, cancer surveillance or with gastrointestinal symptoms, other symptoms

Exclusion Criteria

* age under 18 years, pregnancy, breast feeding, prior history of surgical large bowel resection, severe renal failure (creatinine ≥ 3.0mg/dL (normal 0.8-1.4)), drug addiction or major psychiatric illness; allergy to PEG, refusal of consent to participate in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Inje University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eun Hee Seo

fellow

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tae Oh Kim, Ph.D.

Role: STUDY_DIRECTOR

Inje University School of Medicine, Haeundae Paik Hospital, Internal Medicine

Eun Hee Seo, M.D.

Role: PRINCIPAL_INVESTIGATOR

Inje University School of Medicine, Haeundae Paik Hospital, Internal Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Haeundae Paik Hospital

Busan, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HGI 2011-02

Identifier Type: -

Identifier Source: org_study_id